If you haven’t taken action yet, please do so now! We have also heard that the Wyeth is already gearing up to fight this tooth and nail. We have also learned that Wyeth is coordinating women’s groups to write letters in opposition of the resolution. We need you to help spread the word and fight Big Pharma and their controlling ties to the FDA.
The American Association for Health Freedom has been very disappointed with the Food and Drug Administration’s (FDA) actions towards bio-identical hormones this year.
You might remember that on January 9, 2008, the FDA sent numerous pharmacies, large and small, an order to stop using Estriol, and the term “bio-identical” in their hormone replacement formulas. This was an unprecedented attack on compounders, patients and physicians because until then NO compounded drug component with a USP monograph had been withdrawn from circulation unless there had been evidence of harm to patients. Yet that is what the FDA did. The FDA admitted in their press conference that there is no evidence of harm to any patient from the use of Estriol in compounds. If they can do it to Estriol, they can do it to anything they wish to!
This week, the U.S. Congress is taking a key first step toward reigning in the FDA’s astounding actions against women’s health and we need your support!
Congressman Mike Ross (D-AR), and other notable members of the U.S. House of Representatives, have taken the step of sponsoring House Concurrent Resolution 342. This resolution calls upon the FDA to stop their new policy of restricting women’s access to prescriptions containing estriol. This drug has been available in the United States for half a century and is the chemically the same as that made in a woman’s body.
This is one of our best courses of action to restore estriol’s availability to the market.
The resolution also calls on the need of FDA to respect the physician-patient relationship and recognizes that doctors, not the FDA, are in the best position to determine which medications are appropriate for their patients. It also points out that the FDA has acknowledged that it is unaware of any adverse events associated with the use of estriol over the past three decades.